Aspectos relacionados con la inmunopatogenia y el diagnóstico en las fases de la neurocisticercosis: múltiples interrogantes, pocas respuestas

ENGELS D, URBANI C, BELOTTO A, MESLIN F, SAVIOLI L. The control of human (neuro)cysticercosis: which way forward? Acta Trop 2003;87:177-182.

KELVIN E., CARPIO A, BAGIELLA M, DENISSE L, PIETRO L, HOWARD A, HAUSER A. Seizure in people with newly diagnosed active or transitional neurocysticercosis. Seizure 2011;20:119-125.

KELVIN E., CARPIO A, BAGIELLA M, DENISSE L, PIETRO L, HOWARD A, HAUSER A. Investigation of familial aggregation of seizures in neurocysticercosispatients. Epilepsy Research 2009; 84:67-71.

TAKAYANAGUI OM, LEITE JP. Neurocisticercose. Rev Soc Bras Med Trop 2001;34:283-290.

CAMARGO J, FERREIRA P. Quantification of Fas protein in CSF of patients with neurocysticercosis. Arq Neuropsiquiatr 2012;70:262-266.

CARPIO A. Neurocysticercosis: an update. Lancet Infect Dis 2002; 2:751-762.

RODRIGUES V JR., DE MELL FA, MAGALHÃES E, RIBEIRO S,MARQUEZ J. Interleukin-5 and interleukin-

are major cytokines in cerebrospinal fluid from patients with active neurocysticercosis. Braz J Med Biol Res 2000; 33:1059-1063.